Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Sep;22(3):431–441. doi: 10.1128/aac.22.3.431

Capacity of deoxycytidine to selectively antagonize cytotoxicity of 5-halogenated analogs of deoxycytidine without loss of antiherpetic activity.

L M Fox, J A Mekras, C B Bagwell, S B Greer
PMCID: PMC183762  PMID: 6291452

Abstract

Enzyme kinetic studies from this laboratory (M. Dobersen and S. Greer, Biochemistry 17:920-928, 1978) suggested that deoxycytidine could antagonize the toxicity of 5-halogenated analogs of deoxycytidine without interfering with their antiviral activity. Antagonism by deoxycytidine of the toxicity of 5-chlorodeoxycytidine without impairing its anti-herpes simplex virus type 2 activity is demonstrated in the present studies. Tetrahydrouridine, an inhibitor of cytidine deaminase, was utilized. The high Km for deoxycytidine (0.6 mM) with respect to the herpes pyrimidine nucleoside kinase as compared with the low Km for 5-chlorodeoxycytidine (1.1 microM) accounts for the absence of antagonism of the antiviral activity. The high Km for 5-chlorodeoxycytidine (56 microM) as compared with the low Km of deoxycytidine (2 microM) with respect to mammalian deoxycytidine kinase accounts, in great part, for the antagonism of toxicity. In addition, antagonism of toxicity by deoxycytidine is the result of factors other than the kinetic parameters of nucleoside kinases, as indicated by its antagonism of the cytotoxicity of 5-chlorodeoxyuridine. This may be attributed to replenishment of low dCTP pools, diminished because of effector inhibition of ribonucleoside diphosphate reductase by Cl-dUTP. Resistance of the herpes-encoded enzymes to effector control may also play a role in the selective antagonism. Cell culture studies with high concentrations of tetrahydrouridine and 2'-deoxytetrahydrouridine suggest that competition by deoxycytidine for deaminases may not play a major role. The fact that deoxycytidine antagonizes the toxicity of chlorodeoxyuridine also argues against competition for the deaminases as a major reason for its effect. Limited studies with a topical herpes simplex virus type 2 infection system indicate heightened efficacy of 5-chlorodeoxycytidine (and tetrahydrouridine) when deoxycytidine is coadministered. The concepts of selective antagonism of a chemotherapeutic agent derived from these studies may be applied to other approaches that extent beyond viral chemotherapy.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebersold P. M. Mutagenic mechanism of 5-bromodeoxyuridine in Chinese hamster cells. Mutat Res. 1976 Sep;36(3):357–362. doi: 10.1016/0027-5107(76)90245-1. [DOI] [PubMed] [Google Scholar]
  2. Ashman C. R., Davidson R. L. Bromodeoxyuridine mutagenesis in mammalian cells is related to deoxyribonucleotide pool imbalance. Mol Cell Biol. 1981 Mar;1(3):254–260. doi: 10.1128/mcb.1.3.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aswell J. F., Allen G. P., Jamieson A. T., Campbell D. E., Gentry G. A. Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro. Antimicrob Agents Chemother. 1977 Aug;12(2):243–254. doi: 10.1128/aac.12.2.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Besmer P., Smotkin D., Haseltine W., Fan H., Wilson A. T., Paskind M., Weinberg R., Baltimore D. Mechanism of induction of RNA tumor viruses by halogenated pyrimidines. Cold Spring Harb Symp Quant Biol. 1975;39(Pt 2):1103–1107. doi: 10.1101/sqb.1974.039.01.125. [DOI] [PubMed] [Google Scholar]
  5. Camiener G. W. Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol. 1968 Sep;17(9):1981–1991. doi: 10.1016/0006-2952(68)90114-7. [DOI] [PubMed] [Google Scholar]
  6. Cheng Y. C. A rational approach to the development of antiviral chemotherapy: alternative substrates of herpes simplex virus Type 1 (HSV-1) and Type 2 (HSV-2) thymidine kinase (TK). Ann N Y Acad Sci. 1977 Mar 4;284:594–598. doi: 10.1111/j.1749-6632.1977.tb21992.x. [DOI] [PubMed] [Google Scholar]
  7. Cheng Y. C. Deoxythymidine kinase induced in the HELA TK- cells by herpes simplex virus type I and type II. Substrate specificity and kinetic behavior. Biochim Biophys Acta. 1976 Dec 8;452(2):370–381. doi: 10.1016/0005-2744(76)90186-8. [DOI] [PubMed] [Google Scholar]
  8. Cheng Y. C., Domin B. A., Sharma R. A., Bobek M. Antiviral action and cellular toxicity of four thymidine analogues: 5-ethyl-,5-vinyl-, 5-propyl-, and 5-allyl-2'- deoxyuridine. Antimicrob Agents Chemother. 1976 Jul;10(1):119–122. doi: 10.1128/aac.10.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cheng Y. C., Goz B., Prusoff W. H. Deoxyribonucleotide metabolism in Herpes simplex virus infected HeLa cells. Biochim Biophys Acta. 1975 May 16;390(3):253–263. doi: 10.1016/0005-2787(75)90346-9. [DOI] [PubMed] [Google Scholar]
  10. Cheng Y. C., Grill S., Ruth J., Bergstrom D. E. Anti-herpes simplex virus and anti-human cell growth activity of E-5-propenyl-2'-deoxyuridine and the concept of selective protection in antivirus chemotherapy. Antimicrob Agents Chemother. 1980 Dec;18(6):957–961. doi: 10.1128/aac.18.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cheng Y. C., Ostrander M. Deoxythymidine kinase induced in HeLa TK- cells by herpes simplex virus type I and type II. II. Purification and characterization. J Biol Chem. 1976 May 10;251(9):2605–2610. [PubMed] [Google Scholar]
  12. Cohen G. H., Factor M. N., Ponce de Leon M. Inhibition of herpes simplex virus type 2 replication by thymidine. J Virol. 1974 Jul;14(1):20–25. doi: 10.1128/jvi.14.1.20-25.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cohen G. H. Ribonucleotide reductase activity of synchronized KB cells infected with herpes simplex virus. J Virol. 1972 Mar;9(3):408–418. doi: 10.1128/jvi.9.3.408-418.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cohen R. M., Wolfenden R. Cytidine deaminase from Escherichia coli. Purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J Biol Chem. 1971 Dec 25;246(24):7561–7565. [PubMed] [Google Scholar]
  15. Cooper G. M., Greer S. Phosphorylation of 5-halogenated deoxycytidine analogues by deoxycytidine kinase. Mol Pharmacol. 1973 Nov;9(6):704–710. [PubMed] [Google Scholar]
  16. Cooper G. M. Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3788–3792. doi: 10.1073/pnas.70.12.3788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Coppey J. Common precursor pathways of Herpes DNA and of repair synthesis in ultraviolet irradiated cells. Nature. 1977 Jan 20;265(5591):260–261. doi: 10.1038/265260a0. [DOI] [PubMed] [Google Scholar]
  18. De Clercq E., Shugar D. Antiviral activity of 5-ethyl pyrimidine deoxynucleosides. Biochem Pharmacol. 1975 May 15;24(10):1073–1078. doi: 10.1016/0006-2952(75)90192-6. [DOI] [PubMed] [Google Scholar]
  19. Dobersen M. J., Greer S. Herpes simplex virus type 2 induced pyrimidine nucleoside kinase: enzymatic basis for the selective antiherpetic effect of 5-halogenated analogues of deoxycytidine. Biochemistry. 1978 Mar 7;17(5):920–928. doi: 10.1021/bi00598a028. [DOI] [PubMed] [Google Scholar]
  20. Dobersen M. J., Jerkofsky M., Greer S. Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine. J Virol. 1976 Nov;20(2):478–486. doi: 10.1128/jvi.20.2.478-486.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Greer S., Schildkraut I., Zimmerman T., Kaufman H. 5-Halogenated analogs of deoxycytidine as selective inhibitors of the replication of herpes simplex viruses in cell culture and related studies of intracranial herpes simplex virus infections in mice. Ann N Y Acad Sci. 1975 Aug 8;255:359–365. doi: 10.1111/j.1749-6632.1975.tb29243.x. [DOI] [PubMed] [Google Scholar]
  23. Hanze A. R. Nucleic acids. IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors). J Am Chem Soc. 1967 Dec 6;89(25):6720–6725. doi: 10.1021/ja01001a057. [DOI] [PubMed] [Google Scholar]
  24. Jamieson A. T., Bjursell G. Deoxyribonucleoside triphosphate pools in cells infected with deoxypyrimidine kinaseless herpes simplex virus. J Gen Virol. 1976 Apr;31(1):115–123. doi: 10.1099/0022-1317-31-1-115. [DOI] [PubMed] [Google Scholar]
  25. Jamieson A. T., Bjursell G. Deoxyribonucleoside triphosphate pools in herpes simplex type 1 infected cells. J Gen Virol. 1976 Apr;31(1):101–113. doi: 10.1099/0022-1317-31-1-101. [DOI] [PubMed] [Google Scholar]
  26. Jerkofsky M. A., Dobersen M. J., Greer S. Selective inhibition of the replication of varicella-zoster virus by 5-halogenated analogs of deoxycytidine. Ann N Y Acad Sci. 1977 Mar 4;284:389–395. doi: 10.1111/j.1749-6632.1977.tb21975.x. [DOI] [PubMed] [Google Scholar]
  27. Kaufman E. R., Davidson R. L. Biological and biochemical effects of bromodeoxyuridine and deoxycytidine on Syrian hamster melanoma cells. Somatic Cell Genet. 1978 Sep;4(5):587–601. doi: 10.1007/BF01542928. [DOI] [PubMed] [Google Scholar]
  28. Kelman A. D., Capozza F. E., Kibrick S. Differential action of deoxynucleosides on mammalian cell cultures infected with herpes simplex virus types 1 and 2. J Infect Dis. 1975 Apr;131(4):452–455. doi: 10.1093/infdis/131.4.452. [DOI] [PubMed] [Google Scholar]
  29. Labrecque R., Thirion J. P. Action of FdUrD and dCyd on the incorporation of BrdUrd in chinese hamster somatic cell DNA and the isolation of auxotrophic mutants. J Cell Physiol. 1977 Feb;90(2):321–327. doi: 10.1002/jcp.1040900217. [DOI] [PubMed] [Google Scholar]
  30. Lopez C., Watanabe K. A., Fox J. J. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803–806. doi: 10.1128/aac.17.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Maley F., Maley G. F. Tetrahydrodeoxyuridylate: a potent inhibitor of deoxycytidylate deaminase. Arch Biochem Biophys. 1971 Jun;144(2):723–729. doi: 10.1016/0003-9861(71)90379-1. [DOI] [PubMed] [Google Scholar]
  32. Meuth M., Green H. Induction of a deoxycytidineless state in cultured mammalian cells by bromodeoxyuridine. Cell. 1974 Jun;2(2):109–112. doi: 10.1016/0092-8674(74)90099-3. [DOI] [PubMed] [Google Scholar]
  33. Neil G. L., Moxley T. E., Manak R. C. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Cancer Res. 1970 Aug;30(8):2166–2172. [PubMed] [Google Scholar]
  34. Ponce de Leon M., Eisenberg R. J., Cohen G. H. Ribonucleotide reductase from herpes simplex virus (types 1 and 2) infected and uninfected KB cells: properties of the partially purified enzymes. J Gen Virol. 1977 Jul;36(1):163–173. doi: 10.1099/0022-1317-36-1-163. [DOI] [PubMed] [Google Scholar]
  35. ROIZMAN B., ROANE P. R., Jr A physical difference between two strains of herpes simplex virus apparent on sedimentation in cesium chloride. Virology. 1961 Sep;15:75–79. doi: 10.1016/0042-6822(61)90079-4. [DOI] [PubMed] [Google Scholar]
  36. Renis H. E. Comparison of cytotoxicity and antiviral activity of 1-beta-D-arabino-furanosyl-5-iodocytosine with related compounds. Cancer Res. 1970 Jan;30(1):189–194. [PubMed] [Google Scholar]
  37. Roller B., Cohen G. H. Deoxyribonucleoside triphosphate pools in synchronized human cells infected with herpes simplex virus types 1 and 2. J Virol. 1976 Apr;18(1):58–64. doi: 10.1128/jvi.18.1.58-64.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ross D. D., Akman S. A., Schrecker A. W., Bachur N. R. Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools. Cancer Res. 1981 Nov;41(11 Pt 1):4493–4498. [PubMed] [Google Scholar]
  39. Schildkraut I., Cooper G. M., Greer S. Selective inhibition of the replication of herpes simplex virus by 5-halogenated analogues of deoxycytidine. Mol Pharmacol. 1975 Mar;11(2):153–158. [PubMed] [Google Scholar]
  40. Shlomai J., Becker Y. Replication of herpes simplex virus DNA after removal of hydroxyurea block from infected cells. J Gen Virol. 1977 Nov;37(2):429–433. doi: 10.1099/0022-1317-37-2-429. [DOI] [PubMed] [Google Scholar]
  41. Watanabe K. A., Reichman U., Hirota K., Lopez C., Fox J. J. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem. 1979 Jan;22(1):21–24. doi: 10.1021/jm00187a005. [DOI] [PubMed] [Google Scholar]
  42. XEROS N. Deoxyriboside control and synchronization of mitosis. Nature. 1962 May 19;194:682–683. doi: 10.1038/194682a0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES